Protara Therapeutics

Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.